3SBio
3SBio is a leading, fully integrated, profitable biotechnology company focused on researching, developing, manufacturing and marketing.
Launch date
Employees
Market cap
CAD2.2b
Enterprise valuation
CAD2.0b (Public information from Sep 2024)
Share price
HKD5.66 1530.HK
Shenyang Liaoning (HQ)
Financials
Estimates*
CNY | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 5.6b | 6.4b | 6.9b | 7.8b | 8.9b | 9.7b | 10.6b |
% growth | 5 % | 14 % | 7 % | 14 % | 14 % | 9 % | 10 % |
EBITDA | 1.6b | 2.3b | 2.8b | 2.8b | 3.1b | 3.4b | 3.7b |
% EBITDA margin | 29 % | 36 % | 40 % | 36 % | 35 % | 35 % | 34 % |
Profit | 836m | 1.7b | 1.9b | 1.5b | 2.0b | 2.3b | 2.5b |
% profit margin | 15 % | 26 % | 28 % | 20 % | 23 % | 23 % | 23 % |
EV / revenue | 2.7x | 2.1x | 3.0x | 2.4x | 1.4x | 1.1x | 0.7x |
EV / EBITDA | 9.4x | 5.7x | 7.3x | 6.5x | 4.0x | 3.0x | 2.0x |
R&D budget | 590m | 754m | 693m | 795m | - | - | - |
R&D % of revenue | 11 % | 12 % | 10 % | 10 % | - | - | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
N/A | N/A | IPO | |
N/A | N/A | IPO | |
Total Funding | - |
Related Content
Recent News about 3SBio
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by 3SBio
Editexited
exited
ACQUISITION by 3SBio Sep 2017